Amgen, Inc. (AMGN), Astex Pharmaceuticals, Inc. (ASTX), Pharmacyclics, Inc. (PCYC): This Week in Biotech

With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let’s have a look at some of the rulings, studies, and companies that made waves in the sector last week.

Perhaps no story headlined this past week more than the announcement (finally!) that Amgen, Inc. (NASDAQ:AMGN) would be purchasing Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) for $10.4 billion, or $125 a share. After multiple potential bidders dropped out of the running, only Amgen, Inc. (NASDAQ:AMGN) was left standing — and for just $5 more per share than its previous offer. To add icing on the cake to the deal, the EU approved Bayer and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)’s Stivarga on Friday for the treatment of metastatic colorectal cancer. My initial assessment of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) valued the company as high as $145 a share, thanks to strong forecasted growth from Kyprolis in treating multiple myeloma, so I’d certainly say Amgen, Inc. (NASDAQ:AMGN) is getting a pretty good deal.

Amgen, Inc. (NASDAQ:AMGN)

Shareholders in Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) aren’t complaining much, either, with shares rising by double digits after the company reported positive top-line results in a mid-stage study of SGI-110 for acute myeloid leukemia. Based on Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)’s press release, of the 67 patients treated in the trial, 25% demonstrated an overall complete remission rate — nine refractory and relapsed AML patients, and eight treatment-naive patients. Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) plans to release the full details of the study in December, but in the meantime, shareholders have plenty to cheer about.

Speaking of cheering and getting the pompons out, Pharmacyclics, Inc. (NASDAQ:PCYC) announced on Thursday that the Food and Drug Administration had accepted its new drug application filing for ibrutinib, an oral B-cell malignancy drug designed to treat mantle cell lymphoma and chronic lymphocytic leukemia. Not only did the FDA accept ibrutinib, but it’ll also receive a priority review, meaning it could make it to market even faster. The acceptance of Pharmacyclics, Inc. (NASDAQ:PCYC)’ NDA triggers a $75 million milestone payment from its licensing partner Johnson & Johnson.

But, just as we did last week, we’ll end on a sour note with Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), which reported on Monday that R343, an inhaled SYK inhibitor that was in mid-stage trials to treat allergic asthma, failed to meet its primary and secondary endpoints in the study. Although Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) noted that the drug was well tolerated, the primary endpoint of a pre-defined change in pre-bronchodilator FEV1 (a measure of how much air a patient can expel from their lungs within the first second) relative to the placebo was not met. As such, R343 will be shelved and Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders will be forced to chalk up another disappointing study.

The article This Week in Biotech originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool owns shares of, and recommends Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!